The estimated Net Worth of Douglas S Ingram is at least $51.5 Milion dollars as of 3 November 2023. Mr. Ingram owns over 25,225 units of Sarepta Therapeutics Inc stock worth over $50,111,516 and over the last 8 years he sold SRPT stock worth over $0. In addition, he makes $1,387,070 as President, Chief Executive Officer oraz Director at Sarepta Therapeutics Inc.
Douglas has made over 8 trades of the Sarepta Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 25,225 units of SRPT stock worth $2,001,856 on 3 November 2023.
The largest trade he's ever made was buying 47,058 units of Sarepta Therapeutics Inc stock on 27 July 2017 worth over $1,999,965. On average, Douglas trades about 10,470 units every 115 days since 2016. As of 3 November 2023 he still owns at least 390,307 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr. Ingram stock trades at the bottom of the page.
Douglas S. Ingram Esq. serves as President, Chief Executive Officer, Director of the Company. Mr. Ingram has served as our President, Chief Executive Officer and a member of our Board since June 2017. Prior to his appointment, from December 2015 until November 2016, he served as the Chief Executive Officer and President and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Mr. Ingram served as the President of Allergan, Inc., a pharmaceutical company, from July 2013 until it was acquired by Actavis in early 2015. At Allergan, he also served as President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010, where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr. Ingram also served as General Counsel of Allergan from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. With the acquisition of Allergan by Actavis, Mr. Ingram consulted as a special advisor to the Chief Executive Officer of Actavis. Mr. Ingram serves as a director of Pacific Mutual Holding Company, a parent company for subsidiaries engaged in a variety of insurance, financial services and other investment-related businesses, where he is a member of the Compensation Committee, the Governance and Nominating Committee, and the Member Interests Committee. Mr. Ingram received his J.D. from the University of Arizona and his Bachelor of Science degree from Arizona State University.
As the President, Chief Executive Officer oraz Director of Sarepta Therapeutics Inc, the total compensation of Douglas Ingram at Sarepta Therapeutics Inc is $1,387,070. There are 4 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
Douglas Ingram is 57, he's been the President, Chief Executive Officer oraz Director of Sarepta Therapeutics Inc since 2017. There are 7 older and 8 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
Douglas's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 02139.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry oraz M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: